These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 16935041

  • 1. The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load.
    Generali D, Berruti A, Tampellini M, Dovio A, Tedoldi S, Bonardi S, Tucci M, Allevi G, Aguggini S, Milani M, Bottini A, Dogliotti L, Angeli A.
    Bone; 2007 Jan; 40(1):182-8. PubMed ID: 16935041
    [Abstract] [Full Text] [Related]

  • 2. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
    Pollmann D, Siepmann S, Geppert R, Wernecke KD, Possinger K, Lüftner D.
    Anticancer Res; 2007 Jan; 27(4A):1853-62. PubMed ID: 17649784
    [Abstract] [Full Text] [Related]

  • 3. Biochemical picture of bone metabolism in breast cancer patients with bone metastases.
    Berruti A, Torta M, Piovesan A, Raucci CA, Orlandi F, Panero A, Dogliotti L, Angeli A.
    Anticancer Res; 1995 Jan; 15(6B):2871-5. PubMed ID: 8669881
    [Abstract] [Full Text] [Related]

  • 4. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices.
    Woitge HW, Pecherstorfer M, Li Y, Keck AV, Horn E, Ziegler R, Seibel MJ.
    J Bone Miner Res; 1999 May; 14(5):792-801. PubMed ID: 10320528
    [Abstract] [Full Text] [Related]

  • 5. The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease.
    Brown JE, McCloskey EV, Dewar JA, Body JJ, Cameron DA, Harnett AN, Ruutu M, Purohit OP, Tähtelä R, Coleman RE.
    Calcif Tissue Int; 2007 Nov; 81(5):341-51. PubMed ID: 17874331
    [Abstract] [Full Text] [Related]

  • 6. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
    Koizumi M, Takahashi S, Ogata E.
    Anticancer Res; 2003 Nov; 23(5b):4095-9. PubMed ID: 14666607
    [Abstract] [Full Text] [Related]

  • 7. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
    Mountzios G, Dimopoulos MA, Bamias A, Papadopoulos G, Kastritis E, Syrigos K, Pavlakis G, Terpos E.
    Acta Oncol; 2007 Nov; 46(2):221-9. PubMed ID: 17453373
    [Abstract] [Full Text] [Related]

  • 8. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.
    Cremers SC, Papapoulos SE, Gelderblom H, Seynaeve C, den Hartigh J, Vermeij P, van der Rijt CC, van Zuylen L.
    J Bone Miner Res; 2005 Sep; 20(9):1543-7. PubMed ID: 16059626
    [Abstract] [Full Text] [Related]

  • 9. Markers of bone turnover for the management of patients with bone metastases from prostate cancer.
    Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE, Delmas PD.
    Br J Cancer; 2000 Feb; 82(4):858-64. PubMed ID: 10732759
    [Abstract] [Full Text] [Related]

  • 10. Diagnostic value of bone remodeling markers in the diagnosis of bone metastases in patients with breast cancer.
    Pectasides D, Farmakis D, Nikolaou M, Kanakis I, Kostopoulou V, Papaconstantinou I, Karamanos NK, Economopoulos T, Raptis SA.
    J Pharm Biomed Anal; 2005 Feb 07; 37(1):171-6. PubMed ID: 15664758
    [Abstract] [Full Text] [Related]

  • 11. Effect of bed rest during pregnancy on bone turnover markers in pregnant and postpartum women.
    Kaji T, Yasui T, Suto M, Mitani R, Morine M, Uemura H, Maeda K, Irahara M.
    Bone; 2007 Apr 07; 40(4):1088-94. PubMed ID: 17229597
    [Abstract] [Full Text] [Related]

  • 12. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid.
    Pectasides D, Nikolaou M, Farmakis D, Kanakis I, Gaglia A, Kountourakis P, Karamanos NK, Economopoulos T, Raptis SA.
    Anticancer Res; 2005 Apr 07; 25(2B):1457-63. PubMed ID: 15865105
    [Abstract] [Full Text] [Related]

  • 13. Biological variability in serum and urinary indices of bone formation and resorption in dogs.
    Ladlow JF, Hoffmann WE, Breur GJ, Richardson DC, Allen MJ.
    Calcif Tissue Int; 2002 Mar 07; 70(3):186-93. PubMed ID: 11907716
    [Abstract] [Full Text] [Related]

  • 14. First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
    Tosi P, Zamagni E, Cellini C, Parente R, Cangini D, Tacchetti P, Perrone G, Ceccolini M, Boni P, Tura S, Baccarani M, Cavo M.
    Eur J Haematol; 2006 May 07; 76(5):399-404. PubMed ID: 16480429
    [Abstract] [Full Text] [Related]

  • 15. Bone resorption activity of osteolytic metastatic lung and breast cancers.
    Shih LY, Shih HN, Chen TH.
    J Orthop Res; 2004 Nov 07; 22(6):1161-7. PubMed ID: 15475192
    [Abstract] [Full Text] [Related]

  • 16. Determination and biological relevance of serum cross-linked type I collagen N-telopeptide and bone-specific alkaline phosphatase in breast metastatic cancer.
    Kanakis I, Nikolaou M, Pectasides D, Kiamouris C, Karamanos NK.
    J Pharm Biomed Anal; 2004 Mar 01; 34(4):827-32. PubMed ID: 15019061
    [Abstract] [Full Text] [Related]

  • 17. Effects of the circadian variation in serum cortisol on markers of bone turnover and calcium homeostasis in normal postmenopausal women.
    Heshmati HM, Riggs BL, Burritt MF, McAlister CA, Wollan PC, Khosla S.
    J Clin Endocrinol Metab; 1998 Mar 01; 83(3):751-6. PubMed ID: 9506720
    [Abstract] [Full Text] [Related]

  • 18. Biochemical bone turnover markers are useful tools to assess changes in bone metabolism in marmosets.
    Angeliewa A, Budde M, Schlachter M, Hoyle NR, Bauss F.
    J Bone Miner Metab; 2004 Mar 01; 22(3):192-7. PubMed ID: 15108060
    [Abstract] [Full Text] [Related]

  • 19. Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of Cancer.
    Vinholes J, Coleman R, Lacombe D, Rose C, Tubiana-Hulin M, Bastit P, Wildiers J, Michel J, Leonard R, Nortier J, Mignolet F, Ford J.
    Br J Cancer; 1999 Apr 01; 80(1-2):221-8. PubMed ID: 10390000
    [Abstract] [Full Text] [Related]

  • 20. [Bone turnover markers in the detection of bone metastases in primary lung cancer].
    Kong QQ, Tu CQ, Dou QY, Wang JP, Sun TW.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 May 01; 36(3):397-9. PubMed ID: 15931879
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.